Mandy Jackson

Mandy Jackson

Managing Editor, US Commercial News

San Diego, CA

Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.

Latest from Mandy Jackson

Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso

As Sage prioritizes Zurzuvae for postpartum depression after recent setbacks, it will stop selling Zulresso for PPD and no longer pursue Zurzuvae in major depressive disorder.

BMS Sees Growth Products’ Contributions To Total Revenue Increase In Q3

With its two biggest sellers losing exclusivity in 2028, the pressure is on for Bristol Myers Squibb to grow revenue through new products, which made meaningful contributions in Q3.

Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches

Amgen’s product sales grew 24% to $8.15bn in Q3 and its gains are being reinvested in R&D and manufacturing, including for MariTide, which will report Phase II obesity data in late 2024.

Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023

Private Company Edition: Despite a third quarter dip, venture capital investment in biopharma in 2024 is on track to beat 2023, new data confirm. VC mega-rounds of $100m or more helped boost the total, including recent financings totaling $175m for Alpha-9 and $112m for AvenCell.

Finance Watch: Septerna Raises $288m In Public Market Debut

Public Company Edition: In addition to Septerna’s initial public offering, a new life science-focused SPAC went public. Also, Inventiva raised up to €348m ($376.2m), Akeso revealed a $250m private placement and Marinus is exploring strategic alternatives after a Phase III trial failure.

Big Pharma Faces A Big Reality Check In Cell And Gene Therapy

Big pharma executives at ARM’s Cell and Gene Meeting on the Mesa shared some of the practical challenges of bringing one-time treatments to market in hemophilia, cancer and beyond.